Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06879704
Recruiting Not applicable

Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer

NCT06879704 · tracked via the Priya Life Science France tracker
Sponsor
Centre Henri Becquerel
Phase
Not applicable
Started
2025-05-28
Last updated
2026-01-02

Condition(s) studied

Triple Negative Breast Cancer

Investigational drug(s) / intervention(s)

Imaging assessment

Imaging assessment: The patient will have four imaging exam : Ultrasound, angio/mammography, MRI and PET-scan

Study summary

The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells). It also seems important to identify blood markers able to predict which patients will benefit most from treatment, with a view to personalising them, or which patients will be most at risk of toxicities, particularly related to immunotherapy, with a view to personalising monitoring.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Signed informed consent * Patient with histologically proven TNBC * Indication for neo-adjuvant chemo-immunotherapy treatment * Age between 18 and 75 * Affiliated or beneficiary of a social protection scheme Exclusion Criteria: * Pregnant or breast-feeding women * Contraindication to immunotherapy * Inflammatory breast cancer (T4d) * Metastatic patients * Allergies to iodine or gadolinium * Patient with an augmentation prosthesis (for angiography/mammography) * Claustrophobic patients * Renal contraindication to contrast products according to SFR-CIRTACI * Ferromagnetic material * Uncontrolled diabetes (blood glucose \>10 mmol/L) * Patient unable to understand the study for any reason or to comply with the constraints of the trial (language, psychological, geographical problems, etc.). * Patient under guardianship, curatorship or safeguard of justice

Primary outcome measure(s)

  • concordance rate between quadrimodal radiological assessment (ultrasound, angiography/mammography, MRI, PET-CT) and histologically-obtained response following neoadjuvant chemo-immunotherapy in patients with triple-negative breast cancer (TNBC). — two weeks after surgery
    concordance of the response between radiological assessement and histological response

Trial sites (1)

FacilityCityRegionStatus
Centre Henri Becquerel Rouen France Recruiting

More Centre Henri Becquerel trials in France

Impact of Prophylactic Bone Radiation Therapy in Patients With Bone Metastases. Starting soon
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma Active, not recruiting
Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL) Recruiting
Performance of 18F-FDG Micro-PET-CT in the Assessment of Surgical Margins in Head and Neck Cancer Recruiting
Real-Time Monitoring of Circulating Tumor DNA and Study of Prognostic Factors in Patients Treated With CAR-T Cells Active, not recruiting

Other trials for the same condition

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Active, not recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) Recruiting
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06879704 on ClinicalTrials.gov ↗ ← All trials in France